Live Breaking News & Updates on சிமோன் கான்வே நடாலி|Page 1
Stay updated with breaking news from சிமோன் கான்வே நடாலி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Newron Pharmaceuticals S.p.A.: Newron Announces Half-Year 2021 Results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Investegate |Scancell Hlds Announcements | Scancell Hlds: Lindy Durrant appointed CEO of Scancell investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Newron Pharmaceuticals S.p.A.: Newron Announces Paragraph IV ANDA Filings for Xadago (safinamide) in the USA Newron Pharmaceuticals S.p.A. ( Newron ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that with reference to its media release of May 4, 2021, it received further Paragraph IV Notice Letters regarding the submission by a generic manufacturer of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA), seeking approval to engage in the commercial manufacture, use or sale of safinamide mesylate drug product in the U.S. before expiration of certain US patents. Such further Paragraph IV Notice Letters are not unusual and additional similar notices from other generic manufacturers may follow. ....
Newron Pharmaceuticals S.p.A.: Newron Announces Paragraph IV ANDA Filing for Xadago (safinamide) in the USA Newron Pharmaceuticals S.p.A. ( Newron ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it received a Paragraph IV Notice Letter regarding the submission by a generic manufacturer of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA), seeking approval to engage in the commercial manufacture, use or sale of safinamide mesylate drug product in the U.S. before expiration of certain US patents. ....
DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results 01.04.2021 / 07:00 Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to start in April 2021 Milan, Italy and Morristown, NJ, USA, April 1, 2021 - Newron Pharmaceuticals S.p.A. ( Newron ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced initial results from two short-term explanatory studies in evenamide: study 010 in healthy volunteers and study 008 in patients with schizophrenia. ....